COMPASS Pathways’s Crystalline Form Patent
Recently, Compass Pathways issued a press release stating “that it has been granted US Patent No 10,519,175 (“the ‘175 patent”), relating to methods of treating drug-resistant depression with a psilocybin …
Recently, Compass Pathways issued a press release stating “that it has been granted US Patent No 10,519,175 (“the ‘175 patent”), relating to methods of treating drug-resistant depression with a psilocybin …
Investing in psychedelics (e.g., magic mushrooms, psilocybin, etc.) has became a hot topic during 2019. Following Peter Thiel’s investment in Compass Pathway in 2018, several high-profile investors entered the psychedelic …